Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Summary

The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC. Biomarkers related to the efficacy of BPI-9016M will be investigated.

Timeline

Start

2017-03-01

Primary completion

2024-11

Completion

2024-11

Publications

• Hu X, Cui X, Wang Z, Liu Y, Luo Y, Zhong W, Zhao H, Yao M, Jiang D, Wang M, Chen M, Zheng X, Ding L, Wang Y, Yuan X, Wu P, Hu B, Han X, Shi Y. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer. 2023 Apr 11;23(1):331. doi: 10.1186/s12885-022-10500-y.

Drugs

Indications